Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities

References

• Basagaña X, Sunyer J, Kogevinas M, Zock JP, Duran-Tauleria E, Jarvis D, Burney P, Anto JM; European Community Respiratory Health Survey. Socioeconomic status and asthma prevalence in young adults: the European Community Respiratory Health Survey. Am J Epidemiol 2004;160:178–188
   PubMed Web of Science ®Google Scholar
• Afrite A, Allonier C, Com-Ruelle L, Le Guen N, Annesi-Maesano I, Delmas M-C, Furhman C, Leynaert B. Asthma in France in 2006: prevalence and control of symptoms. In: Ed Yann Bourgueil, ed. Issues in health economics No 138. Paris: Institute for Research and Information in health Economics (IRDES); 2008:1–8
   Google Scholar
• Varghese M, Lockey RF. Aspirin-exacerbated asthma. Allergy Asthma Clin Immunol 2008;4:75–83
   PubMedGoogle Scholar
• GINA Report, Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Updated 2011. Available from: http://www.ginasthma.com/GuidelinesResources.asp [last accessed 5 June 2012]
   Google Scholar
• Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther 2007;11:97–104
   PubMed Web of Science ®Google Scholar
• Langmack EL, Martin RJ. Heterogeneity of response to asthma controller therapy: clinical implications. Curr Opin Pulm Med 2010;16:13–18
   PubMed Web of Science ®Google Scholar
• Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010;10:60–66
   PubMed Web of Science ®Google Scholar
• Magnan A, Vervloet D. Anti-leucotrienes (2): place of anti-leucotrienes in asthma and rhinitis pathophysiology. Rev Fr Allergol 1999;39:25–29 [French]
   Google Scholar
• Giouleka P, Papatheodorou G, Lyberopoulos P, Karakatsani A, Alchanatis M, Roussos C, Papiris S, Loukides S. Body mass index is associated with leukotriene inflammation in asthmatics. Eur J Clin Invest 2011;41:30–38
   PubMed Web of Science ®Google Scholar
• Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol 2008;121:1365–1371
   PubMed Web of Science ®Google Scholar
• Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, et al; Childhood Asthma Research and Education Network of the National Heart, Lung, Blood Institute. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003;112:883–892
   PubMed Web of Science ®Google Scholar
• Gogate S, Katial R. Pediatric biomarkers in asthma: exhaled nitric oxide, sputum eosinophils and leukotriene E4. Curr Opin Allergy Clin Immunol 2008;8:154–157
   Google Scholar
• Blake KV. Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 1999;33:1299–1314
   PubMedGoogle Scholar
• Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36:689–703
   PubMed Web of Science ®Google Scholar
• Merck & Co USA. Singulair® full prescribing information. Revised 03/2012. USPI-MF-04761203R023. Available from: http://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf [last accessed 5 June 2012]
   Google Scholar
• ANSM. Summary of Product Characteristics Singulair®. Updated 19/10/2011. [French] Available from: http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid=69863646&typedoc=R&ref=R0200028.htm [last accessed 5 June 2012]
   Google Scholar
• Medicine Compendium UK. Summary of Product Characteristics Singulair®. Last updated on 22/08/2011. Available from: http://www.medicines.org.uk/emc/medicine/17718/SPC/#INDICATIONS [last accessed 5 June 2012]
   Google Scholar
• Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338–344
   PubMed Web of Science ®Google Scholar
• Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67:887–901
   PubMed Web of Science ®Google Scholar
• Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv Ther 2009;26:575–587
   PubMedGoogle Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, et al; Global Allergy and Asthma European Network;Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466–476
   PubMed Web of Science ®Google Scholar
• Busse WW, Casale TB, Dykewicz MS, Meltzer EO, Bird SR, Hustad CM, Grant E, et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 2006;96:60–68
   PubMed Web of Science ®Google Scholar
• Baena-Cagnani CE, Berger WE, DuBuske LM, Gurné SE, Stryszak P, Lorber R, Danzig M. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003;130:307–313
   PubMed Web of Science ®Google Scholar
• Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma 2009;46:413–420
   PubMed Web of Science ®Google Scholar
• Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100:1952–1959
   PubMed Web of Science ®Google Scholar
• Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelson HS. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005;128:1910–1920
   PubMed Web of Science ®Google Scholar
• Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc 2010;31:68–75
   PubMed Web of Science ®Google Scholar
• Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, Reiss TF. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549–1558
   PubMed Web of Science ®Google Scholar
• Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, et al; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211–216
   PubMed Web of Science ®Google Scholar
• Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006;61:737–742
   PubMed Web of Science ®Google Scholar
• Borderias L, Mincewicz G, Paggiaro PL, Guilera M, Sazonov Kocevar V, Taylor SD, Badia X. Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study. Curr Med Res Opin 2007;23:721–730
   PubMed Web of Science ®Google Scholar
• Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, Schellenberg RR, McIvor RA. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16:17A–31A
   PubMedGoogle Scholar
• Korn D, Van den Brande P, Potvin E, Dramaix M, Herbots E, Peché R. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 2009;25:489–497
   PubMed Web of Science ®Google Scholar
• Zhang Q, Thomas M, Wisniewski T, Sazonov Kocevar V, Price D. Treatment and outcomes in patients with asthma and allergic rhinitis in the United kingdom. Int Arch Allergy Immunol 2007;142:318–328
   PubMedGoogle Scholar
• Barnes ML, Menzies D, Fardon TC, Burns P, Wilson AM, Lipworth BJ. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy 2007;62:73–80
   PubMed Web of Science ®Google Scholar
• Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005;99:11–19
   PubMed Web of Science ®Google Scholar
• de Benedictis FM, Vaccher S, de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc) 2008;44:845–855
   PubMed Web of Science ®Google Scholar
• McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994;330:1362–1367
   PubMed Web of Science ®Google Scholar
• Kemp JP. Exercise-induced bronchoconstriction: the effects of montelukast, a leukotriene receptor antagonist. Ther Clin Risk Manag 2009;5:923–933
   PubMedGoogle Scholar
• Grzelewski T, Stelmach I. Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options. Drugs 2009;69:1533–1553
   PubMed Web of Science ®Google Scholar
• Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997;62:556–561
   PubMed Web of Science ®Google Scholar
• Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147–152
   PubMed Web of Science ®Google Scholar
• Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, Cmiel A, Szczeklik A. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2002;32:1360–1365
   PubMed Web of Science ®Google Scholar
• Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006;97:98–104
   PubMed Web of Science ®Google Scholar
• Philip G, Villarán C, Pearlman DS, Loeys T, Dass SB, Reiss TF. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007;44:213–217
   PubMed Web of Science ®Google Scholar
• Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133:424–428
   PubMed Web of Science ®Google Scholar
• Melo RE, Solé D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 2003;111:301–307
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Kim HB, Kim BS, Shim JY, Hong TJ, Hong SJ. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol 2005;39:162–166
   PubMed Web of Science ®Google Scholar
• Peroni DG, Piacentini GL, Ress M, Bodini A, Loiacono A, Aralla R, Boner AL. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 2002;13:434–437
   PubMed Web of Science ®Google Scholar
• de Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006;28:291–295
   PubMed Web of Science ®Google Scholar
• Peroni DG, Pescollderungg L, Sandri M, Chinellato I, Boner AL, Piacentini GL. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Respir Med 2011;105:1790–1797
   PubMed Web of Science ®Google Scholar
• Wasfi YS, Kemp JP, Villarán C, Massaad R, Xin W, Smugar SS, Knorr BA, Philip G. Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast. Allergy Asthma Proc 2011;32:453–459
   Google Scholar
• Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, Garcia-Marcos L. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr Pulmonol 2006;41:222–227
   PubMed Web of Science ®Google Scholar
• Raissy HH, Harkins M, Kelly F, Kelly HW. Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. Pharmacotherapy 2008;28:287–294
   Google Scholar
• Lecheler J, Pfannebecker B, Nguyen DT, Petzold U, Munzel U, Kremer HJ, Maus J. Prevention of exercise-induced asthma by a fixed combination of disodium cromoglycate plus reproterol compared with montelukast in young patients. Arzneimittelforschung 2008;58:303–309
   Google Scholar
• Philip G, Pearlman DS, Villarán C, Legrand C, Loeys T, Langdon RB, Reiss TF. Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. Chest 2007;132:875–883
   PubMed Web of Science ®Google Scholar
• Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, Langley SJ, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999;104:547–553
   PubMed Web of Science ®Google Scholar
• Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000;132:97–104
   PubMed Web of Science ®Google Scholar
• Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM; Challenge-Rescue Study Group. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004;98:1051–1062
   PubMed Web of Science ®Google Scholar
• Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363–368
   PubMed Web of Science ®Google Scholar
• Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002;165:1068–1070
   PubMed Web of Science ®Google Scholar
• Fogel RB, Rosario N, Aristizabal G, Loeys T, Noonan G, Gaile S, Smugar SS, Polos PG. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 2010;104:511–517
   Google Scholar
• Vidal C, Fernandez-Ovide E, Pineiro J, Nunez R, Gonzalez-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2001;86:655–658
   PubMed Web of Science ®Google Scholar
• Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008;121:383–389
   PubMed Web of Science ®Google Scholar
• Carver TW. Exercise-induced asthma: critical analysis of the protective role of montelukast. J Asthma Allergy 2009;2:93–103
   Google Scholar
• National Institutes of Health. Expert Panel Report 3. Guidelines for the diagnosis and management of asthma. NIH Publication No. 07-4051. Bethesda, MD: National Institutes of Health; 2007
   Google Scholar
• Stapleton M, Howard-Thompson A, George C, Hoover RM, Self TH. Smoking and asthma. J Am Board Fam Med 2011;24:313–322
   PubMed Web of Science ®Google Scholar
• Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226–230
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308–1311
   PubMed Web of Science ®Google Scholar
• Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005;60:282–287
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, et al; National Heart Lung and Blood Institute's Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007;175:783–790
   PubMed Web of Science ®Google Scholar
• Montelukast Asthmatic Smoker Study, identifier: NCT00712335, ClinicalTrials.gov (2006). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00712335?intr=%22Montelukast%22&rank=39 [last accessed 5 June 2012]
   Google Scholar
• Sutherland ER. Obesity and asthma. Immunol Allergy Clin North Am 2008;28:589–602
   PubMed Web of Science ®Google Scholar
• Stream AR, Sutherland ER. Obesity and asthma disease phenotypes. Curr Opin Allergy Clin Immunol 2012;12:76–81
   PubMedGoogle Scholar
• Dixon AE, Shade DM, Cohen RI, Skloot GS, Holbrook JT, Smith LJ, Lima JJ, et al; American Lung Association-Asthma Clinical Research Centers. Effect of obesity on clinical presentation and response to treatment in asthma. J Asthma 2006;43:553–558
   PubMed Web of Science ®Google Scholar
• Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med 2007;101:2240–2247
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008;178:682–687
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006;27:495–503
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Camargo CA Jr, Busse WW, Meltzer EO, Ortega HG, Yancey SW, Emmett AH, Stempel DA. Comparative effect of body mass index on response to asthma controller therapy. Allergy Asthma Proc 2010;31:20–25
   PubMed Web of Science ®Google Scholar
• Camargo CA Jr, Boulet LP, Sutherland ER, Busse WW, Yancey SW, Emmett AH, Ortega HG, Ferro TJ. Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. J Asthma 2010;47:76–82
   PubMed Web of Science ®Google Scholar
• O'Byrne PM, Gauvreau GM, Murphy DM. Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma. J Allergy Clin Immunol 2009;124:397–403
   PubMed Web of Science ®Google Scholar
• Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006;6:198–202
   Google Scholar
• Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, Lumry WR, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9–14
   PubMed Web of Science ®Google Scholar
• Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S, Bestynska-Krypel A, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002;32:949–955
   PubMed Web of Science ®Google Scholar
• Lee DK, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 2004;24:226–230
   PubMed Web of Science ®Google Scholar
• Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, DaI Negro RW. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy 2004;59:289–294
   PubMed Web of Science ®Google Scholar
• Schäper C, Noga O, Koch B, Ewert R, Felix SB, Gläser S, Kunkel G, Gustavus B. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol 2011;21:51–58
   PubMed Web of Science ®Google Scholar
• Paganin F, Poubeau P, Yvin JL, Arvin-Berod C. [The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients]. Presse Med 2003;32:978–984
   Google Scholar
• Park JS, Jang AS, Park SW, Lee YM, Uh ST, Kim YH, Cha JY, et al. Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics. Allergy Asthma Immunol Res 2010;2:48–54
   PubMed Web of Science ®Google Scholar
• Pasaje CF, Kim JH, Park BL, Cheong HS, Park TJ, Lee JS, Kim Y, et al. Association of the variants in AGT gene with modified drug response in Korean aspirin-intolerant asthma patients. Pulm Pharmacol Ther 2011;24:595–601
   Google Scholar
• Kim SH, Ye YM, Hur GY, Lee SK, Sampson AP, Lee HY, Park HS. CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Pharmacogenomics 2007;8:1143–1150
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Kim HB, Jin HS, Yu JH, Kim BJ, Kim BS, et al. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin Exp Allergy 2008;38:51–59. Erratum in: Clin Exp Allergy 2008;38:383
   PubMed Web of Science ®Google Scholar
• [Haute Autorité de santé (HAS). Avis de la commission. Singulair 5 et 10mg (comprimé à croquer). Examen du dossier des spécialités inscrites pour une durée de 5 ans par arrêté du 30 décembre 1999 (JO du 1er janvier 2000). Commission de la Transparence, 2005:1–11.]
   Google Scholar
• Farid-Moayer M, Lowe ST. Churg-Strauss Syndrome. Available from: http://emedicine.medscape.com/article/333492-overview [last accessed 31 Jul 2009]
   Google Scholar
• Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691e6–696e6
   Google Scholar
• Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699e8–706e8
   Google Scholar
• Qin P, Mortensen PB, Waltoft BL, Postolache TT. Allergy is associated with suicide completion with a possible mediating role of mood disorder – a population-based study. Allergy 2011;66:658–664
   PubMed Web of Science ®Google Scholar
• Postolache TT, Komarow H, Tonelli LH. Allergy: a risk factor for suicide? Curr Treat Options Neurol 2008;10:363–376
   PubMedGoogle Scholar
• Kelsay K. Assessing risk: data from montelukast clinical trials. J Allergy Clin Immunol 2009;124:697–698
   Google Scholar
• Callero-Viera A, Infante S, Fuentes-Aparicio V, Zapatero L, Alonso-Lebrero E. Neuropsychiatric Reactions to Montelukast. J Investig Allergol Clin Immunol 2012;22:437–459
   Google Scholar
• Storms W, Michele TM, Knorr B, Nooman G, Shapiro G, Zhang J, Shingo S, Reiss TF. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients </= 6 years. Clin Exp Allergy 2001;31:77–87
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Nooman G. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009;44:5685–79
   Google Scholar
• Ciebiada M, Ciebiada MG, Kmiecik T, DuBuske LM, Gorski P. Quality of Life in Patients With Persistent Allergic Rhinitis Treated With Montelukast Alone or in Combination With Levocetirizine or Desloratadine. J Invest Allergol Clin Immunol 2008;18:343–349
   PubMed Web of Science ®Google Scholar
• Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther 2008;30:1026–1035
   PubMed Web of Science ®Google Scholar
• Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF Jr, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355–360
   PubMed Web of Science ®Google Scholar